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ABSTRACT

Delayed Modulation of Glutamate Receptors by Anti-Epileptic Drugs after
Traumatic Brain Injury in Rats
By
Edgar Rodriguez
Advisor: Peter Serrano
Traumatic brain injury (TBI) is a significant health concern. Around 74 million people sustain a
traumatic brain injury worldwide. The damage caused by TBI produces two types of injury;
primary and secondary injuries. Primary injury is caused within milliseconds and is irreversible.
Secondary brain injury is delayed and produced by molecular, cellular, and structural disruption
after the initial injury. One of the most devastating dysfunction after TBI is glutamate
neurotransmitter overactivation that could lead to neurotoxic levels of glutamate in the brain (i.e.,
excitotoxicity). Excitotoxicity has been linked with the development of epilepsy after TBI, also
known as post-traumatic epilepsy (PTE). Several antiepileptic drugs (AEDs) have been clinically
used to reduce the possibility of developing PTE and treating PTE after onset. However, some of
these drugs produce harmful side effects in patients; The presence of harmful side effects has
fueled the search for better pharmacological agents to treat PTE. Levetiracetam (LEV) and, to a
lesser extent, brivaracetam (BREV) are AEDs that have been successful in decreasing the
number of epileptic seizures produced after TBI. The mechanism of actions LEV and BREV are
not fully elucidated; however, recent data suggest that they may affect glutamate transmission by
engaging glutamate transporters and modulating synaptic strength through glutamate α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (AMPAR). Glutamate AMPAR
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subunit GluA1 is a calcium permeable receptor and allows the influx of calcium into the cell; on
the other hand, the GluA2 AMPA receptor is the subunit that regulates the influx of calcium into
the cell. Excessive calcium leads to overactivation of glutamate neurotransmission and
excitotoxicity. A better understanding of the mechanism of these AEDs would help in designing
a better pharmacological strategy. In this study, the controlled cortical impact (CCI) model of
TBI was used to assess the effects of these two AEDs, (LEV and BREV), on glutamate AMPA
receptor subunits GluA1 and GluA2. Animals were divided into four groups, Sham, CCI, and
CCI animals that received either an injection of BREV or LEV. Three weeks later, brains were
harvested, and the hippocampus was analyzed. The CCI model produced a traumatic brain injury
on the right side of the brain. We collected and analyzed the right, injured side, and the left noninjured side of the hippocampus independently. Immunoblots showed an increased expression of
the GluA1 subunit in the CCI non-injured left hippocampus group, a trend of increased protein
in the CCI injured group. GluA2 expression increased in the CCI non-injured group and the LEV
injured group. Additionally, the ratio of protein expression between GluA1 and GluA2 was
evaluated. The findings showed an increase in the use of GluA1 over GluA2 in the CCI injured
side. Overall, the findings suggest that the AED LEV and BREV modulates the levels of
glutamate AMPA receptor expression after TBI, signaling a potential mechanism for preventing
PTE produced by glutamate dysregulation after by TBI.
Keywords: Traumatic brain injury, AMPA receptors, glutamate, anti-epileptic drugs
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1. Traumatic Brain Injury
The Center for Disease Control and Prevention (CDC) has defined TBI as “an injury to the
head arising from blunt or penetrating trauma or from acceleration/deceleration forces” (CDC,
2017). TBI is a major public health issue since it is one of the most common causes of death and
disability in the United States and around the world (CDC, 2017). TBI can be described as a
range of different neurological disruptions resulting from an external force that damages the
brain. TBI injuries cause brain activity dysfunctions and may result in an impaired or changed
level of consciousness. It can also lead to permanent or temporary disabilities of cognitive and
physical functions. TBI produces detrimental health effects with varying degrees of intensity,
length, and clinical manifestation.
1.2 Symptoms
People who had sustained TBI can display a wide range of symptoms and complications
resulting from their injuries. These symptoms can be classified into three different categories:
somatic, sensory and cognitive, and psychological. Somatic symptoms can be described as
symptoms that involve physical and motors (i.e., movement) characteristics such as headaches,
nausea or vomiting, and fatigues or drowsiness. Headaches after TBI are referred to as Posttraumatic headache (PTH), a condition that becomes chronic (CPTH) after the patients
experience headaches for more than two months. About 47-95% of TBI patients reported CPTH
(Defrin, 2014).
TBI can also adversely affect motor behavior, producing a decrease in coordination and
motor function (Caeyenberghs et al., 2011). Moderate to severe TBI can lead to the development
of post-traumatic epilepsy (PTE). PTE can describe as one or more seizures that occur after the

1

first weeks after TBI. Epidemiological investigations have found that PTE is observed in 10–
20% of TBI patients (Lowenstein, 2009)
Sensory symptoms include visual disturbances, auditory dysfunctions, and sensitivity to
light; about 30% to 85% of patients suffering from TBI reported having a visual symptom
(Kapoor & Ciuffreda, 2002). About 75% of patients reported auditory symptoms. One of the
most common symptom reported by civilians and US military personnel after TBI is the auditory
dysfunction known as tinnitus (ringing of the ears) (Kreuzer et al., 2012).
One of TBI symptomology hallmarks is cognitive abilities deterioration, such as a decline
in memory, attention, learning, coordination, and speech. Memory impairment is a widespread
occurrence in patients with TBI, with 20-79% of patients reporting memory impairments, which
can be, either retrograde amnesia, loss of long-term memories or anterograde amnesia, the
inability to form new memories (Dikmen et al., 2009).
Additionally, close to 50% of TBI patients reported a psychological disorder affecting
personality or mood. These disorders are mainly of anxiety and depression and post-traumatic
stress disorder (Juengst, Kumar, & Wagner, 2017), and some patients develop psychosis (Kim et
al., 2007).
1.3. Causes and Incidence
According to the CDC, TBI is caused by “the disruption in the normal function of the
brain that can be caused by a blow to the head, suddenly and violently hitting an object or when
an object pierces the skull and enters brain tissue” (CDC, 2017). TBI can also be caused by an
explosive blast, especially in individuals serving in the U.S. military, referred to in the literature
as combat-related TBI.
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Between 64 and 74 million people are estimated to sustain a TBI worldwide (Dewan et
al., 2018). In the U.S., the CDC has estimated that 2.5 million emergency department visits,
hospitalizations, and deaths were caused by TBI (CDC, 2017). Approximately 2.2 million (87%)
of these cases were treated and released after a visit to the emergency department. Around 284
thousand (11%) were hospitalized and later discharged, and about 53 thousand died. However,
these numbers may underestimate the total incidence of TBI since they do not include persons
serving in the U.S. military or those receiving care at a Veteran Affairs hospital (Faul &
Coronado, 2015). TBI-related injuries may lead to missed workdays and decreased productivity
at work. The economic burden of TBI has been estimated to totaled $221 billion globally. In the
United States, the economic cost of TBI was estimated to be $56 billion (CDC, 2017).
TBI incidence in the U.S is affected by additional factors, including age, gender, and
socio-economic status. Children under the age of four, adolescents between the ages of 15 and19
years, and adults over seventy-five years of age are the groups most likely to visit the emergency
department with a TBI-related injury (Faul & Coronado, 2015). Gender differences are also
observed; males suffer from TBI at a rate double that of females and are four-time more likely to
die due to their injuries (Munivenkatappa, Agrawal, Shukla, Kumaraswamy, & Devi, 2016). TBI
incidence is also significantly higher in economically-disadvantaged populations (Kisser,
Waldstein, Evans, & Zonderman, 2017).
The leading causes of TBI hospitalizations are falls, struck by an object, motor vehicle
accidents, sports-related injuries, and assaults. Approximately 40.5% of all traumatic brain
injuries (TBIs) resulted from falls and, also falls were the most common cause of TBIs. Around
15.5% of all TBIs resulted from unintentional blunt trauma, (e.g., being struck by an object)
(Gardner & Zafonte, 2016). Approximately 14% of all TBIs resulted from motor vehicle
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accidents, which is the leading cause of TBI-related deaths. Firearms are the following most
common cause of TBI fatalities (39%), as only nine percent of cases will survive (Deng et al.,
2019). The estimates of TBIs caused by sport-related injuries are undetermined because of data
collection limitations (CDC, 2011). Additionally, due to military actions in Iraq and Afghanistan,
combat-related TBI is becoming more prevalent as the number of service members affected by
TBI is growing (Lindquist, Love, & Elbogen, 2017). As the number of TBI cases continue to
increase a better understanding of the pathophysiology is needed to develop better treatment
strategies to reduce the destructive symptoms produce by TBI.
2. Traumatic Brain Injury Pathophysiology
Damages to brain tissue associated with TBI can be categorized as: primary injury,
directly resulting from the mechanical forces after the initial injury, and secondary injury, which
is the delayed non-mechanical damages that result in the disruption of normal brain function, cell
death, and cerebral ischemia (Mustafa & Alshboul, 2013).
2.1. Primary Injury
Primary brain injury refers to the sudden and extensive injury to the brain from a violent
collision, acceleration/deceleration, and brain rotational movement. It occurs at the time of
injury, usually within milliseconds (i.e., 100 milliseconds), and it is caused by mechanical forces
(Mustafa & Alshboul, 2013). One type of primary injury is intracranial hematomas. Intracranial
hematomas are the collection of blood within the skull resulting from a head injury. There are
several types of intracranial hematomas, including epidural, subdural, subarachnoid, and
intracerebral hemorrhages. The different types of hematomas are classified based on the place
where they occur (Prichep, Naunheim, Bazarian, Mould, & Hanley, 2015; Steyerberg et al.,
2008). Another type of primary injury is skull fractures, which can be depressed and non-
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depressed dependent on the skull's inward displacement after injury. These fractures are further
classified into single fracture, where there is only one bone fragment, and compound fracture,
when there are multiple bone fragments. Skull fractures cause cranial nerve damage and
cerebrospinal fluid leakage. Primary injury also causes intracranial pressure (ICP), which causes
brain tissue to be compressed within the skull (Haider et al., 2018). Diffuse axonal injury (DAI)
is another type of primary injury; it refers to the impaired function and slow loss of axons within
the area affected by the initial insult (Vieira et al., 2016).
Other than expedited surgical procedures upon arrival to the emergency department,
treatments aimed at preventing primary injuries are not feasible since they occur immediately
after the initial impact (Bullock & Povlishock, 2007); preventing measures such as the use of a
helmet can help prevent initial injury in anticipated circumstances (e.g. riding a bike). A
significant consequence of a primary injury is the immediate damage to the brain circulatory
system. Hemorrhage, edema, blood flow abnormalities, oxygen levels alterations, and blood–
brain barrier (BBB) disruptions are produced almost instantly and are generally seen in patients
and animal models of TBI. What follows after these immediate symptoms are disruptions such as
hypoperfusion, the alteration of metabolic substrates, tissue damage produced by hypoxia and
ischemia; together, these disruptions are classified as secondary brain injuries (Salehi, Zhang, &
Obenaus, 2017).
2.2. Secondary Injury
Most TBI-related in-hospital deaths are associated with secondary injury. Secondary
injury occurs through a cascade of biological reactions caused by primary injury. The majority of
secondary brain injuries are caused by brain swelling or edema, increased ICP, and decreased
blood flow and oxygenation, leading to ischemia (Haider et al., 2018). The resulting effects of
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secondary injury symptoms produce alterations in ionic balance (homeostasis), neurotransmitter
release, such as, glutamate excitotoxicity, neuronal apoptosis, and initiation of inflammatory
responses (Dorsett et al., 2017; Finnie, 2013; Zhang et al., 2013).
Edema is a recurrent symptom in TBI patients, of which there are two types. Vasogenic
edema is caused by the disintegration of the endothelial layer cell of the blood–brain barrier
(BBB) producing an uncontrollable ion and protein movement through the BBB (Jha, Kochanek,
& Simard, 2019). Cytotoxic edema results from the unrestrained and uncompensated influx of
ions through membrane channels. Glial cells and neurons are mainly sensitive to cytotoxic cell
damage (Jha et al., 2019). Both Vasogenic and cytotoxic edema can lead to increase ICP.
Inflammation is another type of secondary injury and can cause alterations in the
secretion of proinflammatory molecules that exacerbate brain damage, hamper brain repair and
neurological functional recovery (Loane & Kumar, 2016). For instance, various proinflammatory
signaling molecules such as cytokines and chemokines have been found to be dysregulated in
animal models of TBI (Finnie, 2013; Zhang et al., 2013).
Glutamate dysregulation that leads to excitotoxicity is another type of secondary injury.
An increasing number of investigations in animals and humans support the hypothesis that TBI
increases extracellular glutamate (Dorsett et al., 2017; McGuire, Ngwenya, & McCullumsmith,
2019). Glutamate is released presynaptically by vesicles or leaks out of the cell due to membrane
damage (e.g., mechanical disruption of the membrane), causing glutamate in the extracellular
space to increase rapidly, allowing an influx of ions into the cell. This ionic alteration
depolarizes the membrane, which activates neurotransmitter release and results in excessive
calcium influx in postsynaptic neurons. This sudden increase in glutamate release and calcium
influx leads to hyperexcitability and neurotoxic levels of glutamate concentration.
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The role of glutamate in TBI is crucial as several experimental and clinical studies reveal
that glutamate levels increase aggressively after TBI, leading to cell damage or cell death,
abnormal transcription factors functions, and dysregulation of essential kinases for brain
function, such as the calcium/calmodulin-dependent protein kinases (CaMKs) (Yamauchi, 2005).
Therefore, understanding the role of glutamate transmission and its dysregulation in TBI is
essential to gain better insights into the cellular and molecular mechanisms affected after brain
injury.
3. Glutamate Dysregulation and Traumatic Brain Injury
The main excitatory neurotransmitter of the adult mammalian brain, glutamate, is
fundamental for the normal execution of numerous molecular and cellular processes in the brain
(Barker-Haliski & White, 2015). It directs most of the excitatory synaptic transmission in the
central nervous system. Glutamate neurotransmission has been implicated in synaptic plasticity
(Meriney & Fanselow, 2019). Synaptic plasticity can be described as the activity-dependent
modification of the strength and efficacy of synaptic transmission (Meriney & Fanselow, 2019).
During frequent activation, the stimulated neurons increase in synaptic efficacy; this
phenomenon is referred to as long-term potentiation (LTP), which is an electrophysiological
model of memory strengthening. In contrast, the decrease in synaptic efficacy is known as longterm depression (LTD). Together, LTP and LTD are proposed to be the foundation for learning
and memory. The dysregulation of glutamate has been linked with cognitive decline, and several
psychiatric and neurodegenerative disorders (Miladinovic, Nashed, & Singh, 2015).
The most-diagnosed mood disorder, major depressive disorder (MDD) has a lifetime
prevalence of 8%- 12% (Hasin et al., 2018). The involvement of glutamate dysregulation has
been corroborated by human studies showing that in MDD patients, the levels of glutamine, an

7

essential amino acid that is converted into glutamate by hydrolyzation, are increased in the
cerebrospinal fluid (CSF) and the levels of glutamate are increased in the serum/plasma (Levine
et al., 2000; Mitani et al., 2006). Magnetic resonance spectroscopy (MRS) results indicate that
glutamate levels are decreased in frontal areas of the brain including the anterior cingulate cortex
and the prefrontal cortex in MDD patients (Hasler et al., 2007).
The neurodevelopmental disorder, Attention-deficit-hyperactivity disorder (ADHD)
affects around 39 million people globally. Association studies of the human genome have
revealed several glutamate receptors and glutamate transporters polymorphisms that are
associated with ADHD (Lesch, Merker, Reif, & Novak, 2013). Glutamate re-uptake and
clearance from the synaptic space has been associated with Alzheimer’s disease (Scott, Pow,
Tannenberg, & Dodd, 2002). Epileptic seizures are also implicated with glutamate dysregulation.
Specifically, the unrestrained release of glutamate that dysregulates the function of glutamate
ionotropic receptors (Barker-Haliski & White, 2015; Graebenitz et al., 2011) can lead to posttraumatic stress (PTS) (Graebenitz et al., 2011). As mentioned above, abnormal glutamate is
linked with several cognitive disorders and epilepsy after TBI; thus, it is important to fully
understand the molecular mechanism of glutamate transmission and how it becomes
dysfunctional after brain injury.
3.1. Glutamate Transmission
Glutamate release, its re-uptake and recycling involves several coordinated actions by
pre- and post-synaptic cells (Martinez-Lozada & Ortega, 2015). Neuronal glutamate is produced
in the cell nucleus de novo via the Krebs cycle and its recycling is carried out by the glutamate–
glutamine cycle (Erecinska & Silver, 1990), 1990). The release of glutamate involves the fusion
of synaptic vesicles with the presynaptic membrane. This process requires the involvement of
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various molecular mechanisms including the N-ethylmaleimide-sensitive fusion protein
attachment protein receptor (SNARE) complex and synaptic membrane proteins such as
syntaxin-1 or syntaxin-2 and SNAP-25 (Antonucci et al., 2016; Popoli, Yan, McEwen, &
Sanacora, 2011). The regulation of glutamate transmission is carried out by activating ionotropic
N-methyl-d-aspartate (NMDA)and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors as well as metabotropic glutamate receptors and the lesser known kainate
receptors. Receptor availability and stability at the synaptic membrane is an important factor in
determining excitatory synaptic transmission because their dysregulation can lead to
overexcitation (Konradi & Heckers, 2003).
Glutamate cannot be degraded by enzymes after being released and needs to be cleared
from the extracellular space by excitatory amino acid transporters (EAATs), which are expressed
and regulated by neighboring glial cells. After being cleared, glutamate is transformed into
glutamine by glutamine synthetase. Glutamine is then carried back into the glutamatergic neuron,
and converted back into glutamate trough glutaminase hydrolyzation, the glutamate-glutamine
cycle (Albrecht, Sidoryk-Wegrzynowicz, Zielinska, & Aschner, 2010). The highly complex
neurotransmission regulation of glutamate renders it susceptible to any kind of molecular
dysfunction. Various pathological conditions have been associated with glutamate abnormal
functioning including schizophrenia, depression, epilepsy (Miladinovic et al., 2015), and TBI
(Dorsett et al., 2017); therefore is important that we understand the extent to which glutamate
transmission is altered during TBI and the effect on glutamate receptors.
3.2. Glutamate Receptors
Glutamate modulates its excitatory activity via several metabotropic and ionotropic
receptors. Metabotropic glutamate receptors (mGluRs 1-8) are G-protein coupled receptors
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(GPCRs) that activate second messengers (Niswender & Conn, 2010). Their involvement in TBI
is still being elucidated.
There are three classes of ionotropic receptors AMPA, NMDA and kainate receptors.
AMPA receptors (AMPARs) are essential for fast excitatory neurotransmission. The NMDA
receptors (NMDARs) facilitate much of the slow postsynaptic excitatory potentials and are
composed of subunits GluN1, GluN2, and GluN3. One fundamental difference between
NMDAR and AMPAR is that the number of NMDAR at the synapse remains fairly stable, as
their recycling is minimal; AMPA receptors on the other hand, are cycled dynamically into and
out of the cell in an activity-dependent manner. Kainate receptors are similar to the AMPAR in
structure, regulation, and ionic selectivity and can modulate both excitatory and inhibitory
activity; however, these receptors' complete functions are still being elucidated (Copits &
Swanson, 2012).
Of particular interest in TBI are the AMPARs as studies show that calcium permeable
(CP) AMPARs (CP-AMPARs) can become dysregulated following ischemic brain injury or
status epilepticus caused by extreme levels of glutamate that could lead to excitotoxicity (Bell,
Ai, Chen, & Baker, 2007; Semyanov & Godukhin, 2001).
3.3. Glutamate Excitotoxicity
Excitotoxicity can be defined as the extreme and unrestrained release of excitatory
neurotransmitters that results in the deterioration of dendrites and cell death. It is triggered by
overactivation of excitatory neurotransmitter receptors, mainly glutamate receptors (Aarts &
Tymianski, 2003). The role of glutamate in excitotoxicity has been known since the late 1950s
when immature adult mice injected with l-glutamate suffered deterioration of the retinal layers
(Lucas & Newhouse, 1957). During the 1960s experiments in other rodents and non-human
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primates demonstrated that different brain regions were also affected by the overproduction of
glutamate (Freedman & Potts, 1962; Olney & Sharpe, 1969). During excitotoxicity, most of the
subcellular components are affected, producing changes in the cytosol, mitochondria and the
nucleus. Elevated levels of glutamate receptor activation can cause neurological damage and can
occur after a neurodegenerative disease, stroke and traumatic brain injury (Dorsett et al., 2017;
Miladinovic et al., 2015).
During the past years, researchers have investigated the role of excess glutamate and its
potential neurotoxic effects during TBI. Using a CCI model of TBI and microdialysis, Folkersma
et al. (2011), found elevated levels of extracellular glutamate shortly after injury compared to
sham animals. Over the following hours, glutamate concentrations levels slowly declined in both
groups, but continued to be higher in CCI rats than in sham rats (Folkersma et al., 2011).
In an elegant set of electrophysiological experiments, Hinzman et al. (2010), found
changing levels of glutamate in various region of the brain in relation to brain injury. Using a
microelectrode array that selectively measures extracellular levels of glutamate, and midline
fluid percussion injury, the experimenters set up to differentiate the concentrations levels of tonic
and evoked glutamate release. They found increases in tonic glutamate release in the in the
dentate gyrus (256%) and dorsal striatum (117%) after moderate injury and increases in evoked
glutamate release in the dorsal striatum (249%) after mild injury compared to sham animals.
These findings suggested that the concentration levels of glutamate signaling were dependent on
the severity of the head injury (Hinzman et al., 2010).
In study with humans, Chamoun et al. (2010) suggested that glutamate levels are
correlated with the mortality rate after TBI (Chamoun, Suki, Gopinath, Goodman, & Robertson,
2010). They measured the changing levels of glutamate after severe head injury hourly for 120
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hours using a microdialysis technique in patients that had suffered a TBI within 48 hours and
used a correlational analysis to assess mortality rates. Their findings were twofold; first, shortly
after injury, the concentration levels of glutamate increased overtime and remain abnormally
high in 30% of their patients, the mortality rate for this group of patients was 39.6%. Second,
glutamate concentration levels increase early after injury but tend to normalize over the
monitoring period of 120 hours, this trend was observed in 71% of patients and mortality rate for
this group was 17% (Chamoun et al., 2010).
The highlighted studies demonstrate that fluctuating levels of glutamate concentration
after TBI are an indicator of not only the severity but also the mortality outcome after TBI.
Glutamate concentration levels might be an important indication when assessing the TBI
severity a devising a therapeutic strategy.
3.4. Effects of Glutamate Excitotoxicity
Several studies have investigated the effects of glutamate excitotoxicity at the molecular
level and have identified several pathways that might lead to the overproduction of glutamate
and the overstimulation of glutamate receptors. These studies highlight several detrimental
effects of excitotoxicity including dysregulation of intracellular calcium homeostasis through
glutamate overstimulation, persistent activation of proteases and increases in expression of
transcription factors and immediate early genes (IEGs) that facilitate death cell (Y. Wang & Qin,
2010).
Studies have shown that one of the principal mechanisms driving excitotoxicity is the
dysregulation of Na+ and Cl2+ level concentration. The overstimulation of glutamate receptors
leads to the overloading of postsynaptic neurons with Na+ and Cl2+, producing lethal levels of
Na+ and Cl2+ (Dong, Wang, & Qin, 2009). The neurotoxic effects of excess glutamate have been
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known from early studies. In a series of in vitro experiments, Tymianski et al. (1993) have
shown that levels of glutamate reach a maximum limit at which single neurons can no longer
regulate their own intracellular levels of Ca2+ and cell death becomes unavoidable (Tymianski,
Charlton, Carlen, & Tator, 1993). Furthermore, Chen et al., (1997) showed that individual and
isolated CA1 hippocampal neurons could be ‘killed’ when overexposed to glutamate and Ca2+;
removing the excess glutamate reduced neuronal death (Q. X. Chen, Perkins, Choi, & Wong,
1997).
Another mechanism of cell death, apoptosis, is the modulation of proteases and kinases.
Calpains and caspases are both cysteine proteases and participate in neuronal apoptosis. Calpains
are calcium dependent proteases and elevated levels of Ca2+ stimulate thier activation. In one
study, Knoblach et, al., (2002), investigated the role of caspase 3, 8 and caspase 9, which are
highly implicated in neuronal apoptosis and are activated by the tumor necrosis factor (TNF)
family death receptors using a lateral fluid-percussion injury model of TBI. Their analysis of
immunoblots identified increases in caspases 3 and 9 but no increases in caspases 8, after 1, 12,
and 48 hours. This finding suggested that these caspases could play a role in the pathophysiology
of TBI (Knoblach et al., 2002). In another study, Wang et al., (2018) used a controlled cortical
impact (CCI) model of TBI in mice to investigate the roles of calpain-1 and calpain-2. Using
immunohistochemistry, they analyzed levels of calpains at various timepoints in CCI and knockout (KO) mice. Their results showed that calpain-1 was activated early after injury and the
activation of calpain-2 was delayed and increased during 8-72 hours after CCI. Calpain-1 KO
enhanced cell death an effect not seeing in calpain-2 KO. The authors suggested that calpain-1
activation suppresses cell death and calpain-2 promotes cell death. Furthermore, injections of
calpain-selective inhibitor, NA101, at 1 and 4 hours after injury reduced calpain-2 activity and
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promoted motor function recovery after TBI (Y. Wang et al., 2018). The inhibitor, NA101, may
be exerting its protective role by preventing the inflammatory response associated with calpain
dysregulation (Ji, Su, & Liu, 2016)
Glutamate has been known to stimulate rapid and transient induction of many immediate
early genes and transcription factors (TF) including c-Fos and c-Jun (Loebrich & Nedivi, 2009).
Recently, there has been an increase in the number of studies investigating TBI and transcription
factors because several studies have found a link between TF and cerebral ischemia and trauma.
Whitfield, & Pickard, (2000) investigated the association of TF and outcome after head injuries
in patients that sustained a head injury. The concentration of TF was analyzed using in-situ
hybridization and immunocytochemistry, 6 hours and 6 days after injury. 50% and 64% of
patients showed expression of c-Fos and c-Jun, respectively, and immunoreactivity for c-Fos
and c-Jun was observed in 67% of patients. The expression of these TFs was associated with
poorer outcomes such as decreases in cognitive abilities and motor functions (Whitfield &
Pickard, 2000).
Additionally, apoptosis and necrosis are observed as results of TBI. Necrosis follows a
severe mechanical injury or ischemic/hypoxic states after TBI resulting from the extreme and
unrestrained release of excitatory neurotransmitters (i.e., glutamate) and metabolic dysfunctions
(Nathoo et al., 2004). On the other hand, apoptosis can be enhanced following activation of some
caspases, such as interleukin-converting enzymes which are essential mediators of programmed
cell death (Eldadah & Faden, 2000).
The studies emphasized above described some of the mechanisms of glutamate
excitotoxicity and its impact on different molecular processes. Such processes are evidently
dysregulated during TBI, which is why it is important to consider excitotoxicity as a
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symptomatic manifestation of the severity of the injury. The dysregulation of glutamate
transmission appears to have overwhelmed the activity of glutamate receptors which could lead
to overactivation of the different receptor types, mainly AMPAR.
3.5. Glutamate AMPA Receptors
AMPAR provide the primary depolarization necessary to permit calcium entry into the
cell. AMPAR are ligand-gated ion channels that allow Na+, K+, and Ca2+ influx upon binding to
glutamate, causing membrane depolarization (Meldrum, 2000). Excessive glutamate
concentration levels cause hyperactivation of AMPAR, leading to ionic imbalance by allowing
extracellular Ca2+ into the postsynaptic cell. This excess Ca2+ produces toxic levels of glutamate
neurotransmitter release that builds up in the synaptic space. AMPARs are tetrameric complexes
formed by combining four homologous subunits: GluA1, GluA2, GluA3, and GluA4. Of the four
subunits, three are calcium-permeable AMPA; subunits, GluA1,3,4, and can be expressed as
homomers (composed of one subunit) and heteromers (composed of different subunits),
(Passafaro, Piech, & Sheng, 2001; Shi, Hayashi, Esteban, & Malinow, 2001). The only calcium
non-permeable subunit is the GluA2 subunit which has the following characteristics: [1] it is the
rate-limiting factor for calcium influx and regulates calcium influx into the cell (Isaac, Ashby, &
McBain, 2007), [2] it is highly expressed in the hippocampus as GluA1/GluA2 and
GluA2/GluA3 heteromers, (Murphy, Tcharnaia, Beshara, & Jones, 2012); [3] it is essential for
learning and memory (Joels & Lamprecht, 2010), and [4] it contributes to the restoration of
homeostatic ionic balance (Ancona Esselmann, Diaz-Alonso, Levy, Bemben, & Nicoll, 2017;
Zanca et al., 2019).
GluA2 homomers are continuously cycled on and off the synaptic membrane and are
trafficked rapidly to this area in order to respond to fast synaptic activation (Passafaro et al.,
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2001), or when glutamate release is unregulated, for example., excitotoxicity (Atkins, Chen,
Alonso, Dietrich, & Hu, 2006). In animal studies, following the unrestrained release of
glutamate, the GluA1 subunit, in its phosphorylated form, increases rapidly four hours after
initial injury; this leads to aberrant channel conductivity (Atkins et al., 2006). Furthermore,
GluA2 endocytosis has been observed after in vitro TBI, which increases Ca2+ permeability (Bell
et al., 2007).
Additional studies in humans indicate that AMPAR are highly associated with the
development of epilepsy after TBI, as their function becomes dysregulated after unrestrained
release of glutamate. For instance, Graebenits et al. (2011) found that blockage of AMPAR, but
not NMDAR, inhibit electrical activity between seizures (Graebenitz et al., 2011). In addition,
previous research has found that expression of the GluA1-receptor subunit is elevated in the
hippocampus of epileptic patients and positively correlated with axonal sprouting (Ying, Babb,
Comair, Bushey, & Touhalisky, 1998). The hippocampus has been long regarded as a region
vulnerable to damage after TBI. The effects of hippocampal damage after TBI include severe
neuronal loss in the CA1 and increased structural reorganization of excitatory synaptic contacts
in the dentate gyrus. Both mechanisms contribute to the development of PTE by downregulating
inhibition due to neuronal loss and increasing hyperexcitability through an abnormal function of
newly formed synaptic contacts (Sharma, Tiarks, Haight, & Bassuk, 2021). Furthermore,
AMPARs are highly expressed in this region, and their dysregulation has also been observed in
PTE development (Atkins et al., 2006; Bell et al., 2007).
Studies of AMPAR suggest that AMPARs are critically involved in PTE's progression;
however, the functions of these receptors have not been investigated extensively, and more
research is necessary to explore the molecular mechanisms that leads to abnormal activity of the
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AMPAR following TBI and how these mechanisms can be modulated to ameliorate the negative
effects produce by PTE.
4. Traumatic Brain Injury and Post-Traumatic Epilepsy
The occurrence of seizures after a head injury is a recognized complication of TBI. TBI is
the third most common cause of all epilepsies and results from primary and secondary damage to
the brain (Fordington & Manford, 2020; Kaur & Sharma, 2018). Immediately after injury, the
brain suffers from a range of molecular, cellular, and structural disruptions, which could play a
role in PTE development. PTE is defined as one or more unprovoked seizures that occur during
the course of a whole week after TBI (Verellen & Cavazos, 2010). PTE accounts for high
morbidity and mortality in the early stages following TBI and is the leading cause of death
several years after TBI injury (Rao & Parko, 2015). An epidemiological study reports that PTE is
observed in 10–20% of TBI patients (Lowenstein, 2009). TBI resulting in focal or diffuse injury
to the brain can trigger epileptogenesis through a dysfunctional mechanism such as the
uninhibited release of glutamate, causing excitotoxic cell death via excessive calcium release.
As mentioned above, fast excitatory synaptic transmission is primarily achieved via
regulation of glutamate release presynaptically or via postsynaptic strengthening or weakening of
the connections formed at the synapses through the interaction with AMPARs. Neuronal circuit
activity can regulate the quantity, synaptic localization (externalized or internalized from the
neuron), and subunit composition of AMPARs. Thus, neurons can strengthen or weaken their
response to excitatory input (Barker-Haliski & White, 2015). Elevated levels of glutamate can
destabilize the synapse by producing externalization or internalization of the AMPAR, leading to
aberrant neuronal activity, that can cause epileptogenesis (Isaac et al., 2007).
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4.1. Post-traumatic Epilepsy (PTE) and AMPAR dysfunction
Post-traumatic epilepsy (PTE) is a life-long complication of traumatic brain injury (TBI).
Findings of animal studies are consistent with a role for AMPA receptor activation in the
development of epilepsy. Atkins et al. (2006) found that GluA1 receptors become more
upregulated after TBI, which leads to an increased level of calcium into the cell and the
uninhibited activation of the calcium/calmodulin-dependent protein kinases (CAMKs) (Atkins et
al., 2006). Additionally, Bell et al. (2009), using an in-vitro and in-vivo TBI models, observed
decreases in the GluA2 subunit (Bell, Park, Ai, & Baker, 2009). The reduction of GluA2 allows
for increased intracellular calcium influx (Isaac et al., 2007).
The role of AMPA receptors in epilepsy has been elucidated by a study in humans. A
pharmacological investigation of the lateral amygdala was coupled with electrophysiological
recordings of patients with medically intractable temporal lobe epilepsy. In this study, blockade
of AMPA receptors inhibited electrical activity between seizures (interictal activity), suggesting
that AMPA, and not NMDA receptors, may play a role abnormal electrical activity in the
epileptic brain. (Graebenitz et al., 2011). Additionally, investigations have also looked at
AMPA-receptor subunit expression in humans. Ying et al. demonstrated that expression of the
GluA1- is elevated in the epileptic hippocampus (Ying et al., 1998). These studies contribute to
the view that AMPAR dysfunction plays an essential role in the development of PTE.
5. Treatment for Traumatic Brain Injury
Because primary injury after TBI cannot be reversed, a window of opportunity to
minimize and prevent further neurological damage arises in TBI: treating secondary brain injury.
Different pharmacological strategies have been proposed to treat TBI, including the prevention
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of glutamate release, calcium channel blockers, glutamate receptor antagonists, and several
antiepileptic drugs (AED).
The glutamate inhibition via cannabinoid mechanisms has been studied in several
investigations with findings reporting the endogenous cannabinoid 2-arachidonoyl glycerol to
have neuroprotective qualities. (Panikashvili et al., 2001, 2005, 2006). In a clinical study by
Knoller et al. (2002), the effect of dexanabinol (HU-211) was examined in a small, randomized
trial in phase II. Patients suffering from TBI were administered a single dose of 150 mg of
dexanabinol 4-6 hours after initial injury or were given a placebo. One month after the treatment,
the number of patients achieving good recovery was significantly greater in the treatment group;
however, the initial recovery leveled off after six months. No discernible differences between the
treatment and placebo groups were found (Knoller et al., 2002). In a larger dexanabinol phase III
clinical trial, which included 861 patients, the authors concluded that there were no clinical or
statistical effects on patient improvement after six months (Maas et al., 2006).
Calcium channel blockers have also been used in an attempt to prevent prolonged
cerebral damage after TBI. These blockers would, in theory, abolish the harmful effects caused
by excessive calcium influx. Berman et al. (2000) investigated the effects of the calcium channel
blocker, Ziconotide, in an animal model. A total of 6 mg of Ziconotide was injected at various
times after initial injury: 2 mg after 3, 5, and 24 hours. The authors demonstrated that Ziconotide
exhibits substantial neuroprotective activity in this TBI model. Specifically, improvement was
observed in both motor and cognitive tasks (Berman, Verweij, & Muizelaar, 2000). Randomized
control trials of the calcium blockers nimodipine and nicardipine have reduced subarachnoid
bleeding and a provide a possible neuroprotective role after neurological injuries (TreggiariVenzi, Suter, & Romand, 2001). However, in a meta-analysis of randomized controlled trials, the
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authors indicated that there was insufficient evidence to support the use of calcium channel
blockers in the treatment of TBI (Langham, Goldfrad, Teasdale, Shaw, & Rowan, 2003).
In vivo and in vitro studies have demonstrated the benefits of glutamate receptor
antagonists. Dizocilpine, an NMDA noncompetitive receptor antagonist, given immediately after
TBI, was found to decrease hippocampal cell loss and anxiety-like responses two months after
initial injury (Sonmez, Sayin, Gurgen, & Calisir, 2015). Furthermore, a similar drug, memantine,
also prevented hippocampal neuronal loss (Rao & Parko, 2015), decreased motor deficits, and
regulated the NMDAR subunits' levels (Y. Wang et al., 2018). Noncompetitive AMPAR
antagonists have also been evaluated in TBI animal models. For instance, administering the drug
talampanel intravenously continuously for 72 hours reduced neuronal loss in the CA1 region of
the hippocampus (Belayev et al., 2001). Another drug of the same class, perampanel, also
ameliorated brain edema, motor function and reduced the expression of cytokines TNF-α and IL1β, which are pro-inflammatory markers (T. Chen et al., 2017). However, despite these findings
with animal studies, several clinical trials have shown insufficient evidence of the
neuroprotective effects of glutamate receptor antagonists (Muir, 2006), which has led to the
search for better pharmacological agents including AEDs.
AEDs have been studied for their potential neuroprotective role in TBI. AEDs have
shown their beneficial effects in animal models. For instance, the acute administration of the
AED phenytoin (PHT) has been shown to reduce hippocampal cell loss and improve motor
function (Darrah et al., 2011). In clinical settings, PHT is the go-to treatment after TBI (Chang
(Chang, Lowenstein, & Quality Standards Subcommittee of the American Academy of, 2003)
However, its high chance for potential side effects (i.e., anticonvulsant, hypersensitivity, tissue
necrosis) has led to the adoption of other AEDs for TBI treatment including valproate and
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carbamazepine (Torbic, Forni, Anger, Degrado, & Greenwood, 2013). Another promising AED,
levetiracetam (LEV), has been used in animal models and clinical trials (Cereghino et al., 2000;
Yan et al., 2005). LEV treatment in CCI models shows decreased neuronal loss and improved
motor function (Shetty, 2013; Zou et al., 2013). A randomized clinical trial comparing PHT and
LEV revealed that patients in the LEV group showed improved long-term outcomes (Szaflarski,
Sangha, Lindsell, & Shutter, 2010). Additionally, LEV treatment led to reduction in the number
of days patients were hospitalized compared to PHT; furthermore, LEV showed reduced side
effects (Harris, Hateley, Tsang, Wilson, & Seemungal, 2020). Recently, the AED Brivaracetam
(BREV), a LEV analog, has received increasing attention, because it is thought to have superior
neuroprotective effects and high tolerability (Hirsch, Hintz, Specht, & Schulze-Bonhage, 2018).
These pharmacological treatments are being implemented as early treatment to mitigate the
effects of PTS; however, the molecular mechanisms of actions are not well elucidated (H. Wang
et al., 2006; Zou et al., 2013). A better insight on how these drugs target the brain’s molecular
machinery could help minimize the side effects and increase the benefits of pharmacological
intervention.
6. Current Study
Glutamate excitotoxicity is a major contributor to secondary injury and PTE. Therefore, it
is essential that we gain better insights into the dysfunctional overactivation of glutamate
AMPAR, which could lead to PTE. This study investigates the effects of AEDs LEV, and BREV
on the expression of the glutamate AMPAR subunits GluA1 and GluA2. GluA1 increases rapidly
after initial brain injury, and GluA2 has tight control over the ionic properties of the AMPAR.
AMPAR dysregulation may lead to the development of PTE. This investigation uses an animal
model in which TBI is induced via controlled cortical injury (CCI) to assess the delayed effect of
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TBI on AMPAR expression in the hippocampus. For this investigation, a biochemical assay is
used to quantify the levels of protein expression. Both the injured hippocampus and the noninjured hippocampus were examined. The report examines the hypothesis that both LEV and
BREV contribute to the modulation of subunits GluA1 and GluA2 after TBI in a distinctive way
in the injured and non-injured hippocampus.
7. Methods
7.1. Subjects
Young (postnatal day 24–32) Sprague Dawley rats of either sex were used for this study.
Animal quarters were maintained at constant temperature (22 ± 1°C) and relative humidity (40–
50%) with a 12 h light/dark cycle (lights on at 08:00 h). Food (Harlan Teklad; Frederick, MD)
and water were available ad libitum, pre- and post-surgery, and during the recovery period.
Subjects were divided into four conditions: Sham (control), CCI, levetiracetam plus CCI (LEV
group) and brivaracetam plus CCI (BREV group). All surgeries were performed at State
University of New York (SUNY) Downstate Medical Center, and all the brain analysis was
conducted at Hunter College (Serrano Lab) following the guidelines outlined by the Institutional
Animal Care and Use Committee (IACUC).
7.2. Controlled Cortical Injury (CCI) surgery
Animal models of TBI are crucial to advance our understanding of the damages caused
by TBI. The controlled cortical impact (CCI) model of experimental TBI has been used
extensively because it has provided consistent deficits associated with TBI, including
histological damage and behavioral dysfunctions (Brody et al., 2007; Yang et al., 2010). In the
CCI technique, rodents are anesthetized completely, their skull exposed, and a craniotomy is
performed. Then, an impactor hits the exposed surface of the brain by a fixed distance at a fixed
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velocity yielding the primary injury. Rodents recover well and show low mortality with
reproducible histological lesions in the underlying tissue. The CCI injury in this study was
performed using previously established methods (Brody et al., 2007; V. Sebastian, Estil, Chen,
Schrott, & Serrano, 2013; Yang et al., 2010). Briefly, rats were anesthetized with isoflurane (5%,
inhalation to effect) in oxygen (0.9 L/min) for two minutes and then placed on a stereotaxic
apparatus over a circulating water warming pad (stryker, Kent scientific) then, isoflurane was
adjusted to a constant 3% (inhalation to effect) in oxygen (0.9 L/min) and supplied continuously
until the surgery was over. Rats’ heads were shaven, and povidone-iodine was applied to the
shaven area. Rectal temperature was kept at 37°C with warming pad and feedback controller
(Cell Microcontrols, Norfolk, VA). To protect their vision, ointment was applied to their eyes. A
midline cut was made to expose the skull. Animals were subjected to a 6-mm diameter
craniotomy over the right somatosensory cortex, in the middle from bregma and lambda.
Craniotomy was carefully performed to ensure that the dura remained intact. All surgical tools
were sterilized with a glass bead sterilizer. CCI injury was produced using a cortical impact
device (myNeurolab; St. Louis, MO) with a pneumatic steel impactor tip (5 mm diameter) angled
at 22° from the sagittal plane and perpendicular to the site of injury (Yang et al., 2010). The
impactor tip penetrated the exposed cortex to a depth of 2 mm with a velocity of 4 m/s.
Following CCI injury, isoflurane was reduced to 2% and a sterile plastic skull cap was adhered
to the impact site using veterinary adhesive (vetbond); the skin was sutured closed and antibiotic
ointment was applied (Dugue et al., 2018). Sham operated animals went through the same
craniotomy procedure but did not receive the impact. Rats were fully ambulatory within 60 min
after surgery and no mortalities occurred during the procedure. All subjects received fluids and
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were closely monitored for 6 h post-surgery. All groups continued to be monitored daily until the
end of each experiment (Dugue et al., 2018; Veronica Sebastian, Diallo, Ling, & Serrano, 2013).
7.3. Drug Injections
Immediately after CCI injury (within 0–2 min), rats in the TBI+LEV and TBI+BREV
groups were given a single, intraperitoneal (i.p.) injection of either LEV (150 mg/kg in 0.9%
saline, UCB.SA, Brussels) or BREV (21 mg/kg in 0.9% saline, UCB.SA, Brussels). For all
injections, fresh LEV and BREV solutions were prepared on the day of each CCI procedure
using sterile 0.9% saline.
7.4. Tissue sample collection and subcellular fractionation
Following 3 weeks after CCI, animals were sacrificed. Whole brains were collected and
immediately flash frozen in 2-methyl-butane. Using a dissecting microscope, brain regions were
dissected from the injured and non-injured regions and subsequently prepared into cytosolic and
synaptic fractions as previously reported (Zanca et al., 2019). Briefly, tissues were defrosted and
submerged in TEE (Tris 50 mM; EDTA 1 mM; EGTA 1 mM) buffer prepared with a SigmaFast,
protease inhibitor cocktail (Sigma Aldrich) containing AEBSF (2 mM), Phosphoramidon (1
μM), Bestatin (130 μM), E-64 (14 μM), Leupeptin (1 μM), Aprotinin (0.2 μM), and Pepstatin A
(10 μM). Using a motorized pestle, tissues were homogenized in 200 μl of the TEEhomogenization buffer, each sample was given 20 pumps to guarantee a thorough
homogenization of tissue. Homogenates were transferred to Eppendorf tubes and centrifuged at
3000 g for 5 min at 4 °C. The resulting supernatant was collected and centrifuged at 100,000 g
for 30 min at 4 °C. After ultracentrifugation, the supernatant was collected and stored as the
cytosolic fraction. The remaining pellet was resuspended in 100 μl of homogenizing TEE buffer
containing 0.001% Triton X-100 and placed on ice for 1 hour inside a 4 °C refrigerator. After
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one hour inside the refrigerator, the resuspended pellet was centrifuged at 100,000 g for 1 hour at
4 °C. The resulting pellet was resuspended in 50 μl of TEE buffer, collected and stored as the
synaptic fraction (Nogues et al., 1994). Protein concentrations were determined via Pierce
bicinchoninic acid protein assay (BCA; Thermo Scientific, Rockford, IL, USA). Samples were
subsequent reduced with 4x Laemmli buffer equivalent to 25% of the total volume of the sample
and then boiled and stored frozen at −80 °C.
7.5. Western Blotting
The following protocol was adapted from Zanca et al., 2019 (Zanca et al., 2019). To
resolve alpha-tubulin (55 kDa), GluA1 (102 kDa), and GluA2 (102 kDa), samples of 15 μg were
loaded onto a Tris/Gly 4–20% midi™. The last three or four lanes of each gel were loaded with a
control sample, (all brain samples, ABS). ABS were used to standardize protein signals between
gels for statistical comparison. The IBlot® Dry Blotting System (Life Technologies; Carlsbad,
CA) was used to transferred gels into nitrocellulose membranes. Membranes were then incubated
in blocking solution made of 5% sucrose in Tris Buffered Saline with Tween-20 (TBST; 0.1%
Tween-20 in TBS) for 30 min at room temperature. Samples were incubated with the following
primary antibodies overnight: alpha-tubulin (1:2000; Millipore, Burlington, MA), GluA2
(1:2000; Millipore, Burlington, MA), and GluA1 (1:2000; Millipore, Burlington, MA).
Membranes were washed in TBST for 20 min and probed with Horseradish Peroxidase (HRP)
conjugated secondary antibody. Membranes were incubated with Enhanced Chemiluminescence
(ECL) substrate and exposed on CL-XPosure Film (Thermo Scientific; Rockford, IL). To
standardize protein concentration loaded on gels, α-tubulin was used as control. Films were
scanned for quantification with NIH Image J.
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7.6. Statistical Analysis
All statistical tests were performed using Prism GraphPad 9.3 Statistical Package (La
Jolla, California). Western blot data are mean ± SEM. Analysis of Variance (ANOVA) tests with
pairwise comparisons (Bonferroni corrected) were used to detect group differences.
8. Results
8.1. Hippocampal Synaptic AMPAR GluA1 Expression
Western blot analyses of hippocampal AMPAR subunits GluA1 expression for the
different groups was evaluated using a two-way ANOVA. GluA1 expression following CCI (Fig
1) shows an overall effect of condition (F 3, 54 =13.59, p < .001), an overall effect of site of
injury, GluA1(F 1, 54 =5.60, p < .05), but no significant interaction. For all significant post-hoc
pairwise comparisons, see Table 1. Figure 1 shows higher GluA1 in the injured hemisphere of
the CCI compared to non-inured CCI (t54= 7.057, p < .001). Furthermore, the non-injured side
shows an increase in GluA2 when compare to the BREV non-injured side (t54 =5.742, p < .001),
and the BREV injured side (t54 =6.053, p < .001), and the LEV non-injured (t54 =3.397 , p <
.05), and LEV injured side (t54 =4.196, p < .01). See Table 1 for pairwise comparisons of the
sham condition.
8.2. Hippocampal Synaptic AMPAR GluA2 Expression
Western blot analyses of hippocampal AMPAR subunits GluA2 expression from the
different groups were evaluated using a two-way ANOVA. GluA2 expression following CCI
(Fig 2) shows an overall effect of condition (F 3, 54 =3.81, p < .05), a significant interaction (F
3, 54 =22.87, p < .001), but no significant overall effect of site of injury, (F 1, 54 =1.14, p <
.291). Figure 2 shows higher GluA2 in the injured hemisphere of the CCI compared to CCI in
the non-injured hemisphere. Furthermore, the non-injured side shows a difference when compare
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to the LEV non-injured (t54 = 3.397, p < .05) and LEV injured (t54 =4.195, p < .01), and BREV
CCI injured (t54 =5.742, p < .01), and non-injured group (t54 =6.053, p < .01). Additionally,
there was a decrease in the levels of GluA2 in the CCI injured hemisphere compare to the LEV
injured side (t54 =5.335, p < .001), in the BREV non-injured hemisphere compared to the LEV
injured side (t54 =4.901, p < .001) and between the LEV non-injured side and the LEV injured
side (t54 =3.438, p < .05). See Table 1 for pairwise comparisons of the sham condition.
8.3. Hippocampal Synaptic AMPAR Glua1/GluA2 Ratio
Ratio analyses of hippocampal AMPAR subunits GluA1 and GluA2 expression from the
different groups were evaluated using a two-way ANOVA. GluA2/GluA1 ratio following CCI
(Fig 3) shows an overall effect of condition (F (3, 54) =26.38, p < .001), a significant interaction (F
3, 54

=22.40, p < .001), and a nonsignificant overall effect of site of injury, (F (1, 54) =0.11, p <

.744). The main differences are shown in Figure 3. A decrease in the ratio of GluA1 over GluA2
can be observed in the CCI non-injured hemisphere compare with the CCI injured side (t54
=7.481, p < .001) and in the BREV injured side compare to LEV non-injured side (t54 =4.193, p
< .01). Additionally, an increase in the use of GluA1 over GluA2 can be observed in the CCI
non-injured hemisphere compare to the BREV injured side (t54 =3.754, p = .012), and the LEV
injured side (t54 =3.39, p = .36). Furthermore, an increase can also be observed in the CCI
injured hemisphere compare to the BREV non-injured side (t54 =8.171, p < .001), the BREV
injured side (t54 =11.423, p < .001), the LEV non-injured (t54 =5.292, p < .001). and the LEV
injured side (t54 =9.721, p < .001). See Table 1 for pairwise comparisons of the sham condition.
9. Discussion
In this study, a TBI animal model was used to assess the effects the antiepileptic drugs
LEV and BREV have on AMPAR expression, mainly subunits GluA1, GluA2, and their ratio.
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Immunoblot analysis revealed that the levels of the GluA1 subunit increased in the hippocampus
of animals subjected to CCI. In contrast, there was no discernable difference in GluA1
expression in the remaining groups. The second AMPAR subunit analyzed, GluA2, showed
increased expression levels in the non-injured hippocampus of animals subjected to CCI and in
the LEV injured group. Furthermore, protein expression ratio between GluA1 and GluA2 was
quantified to determine if the upregulation of the subunits differs considerably in the different
conditions and reveals the extent to which each subunit is being trafficked. Analysis of the
subunit ratios showed an increase in the level of the GluA1 subunit in the CCI injured side group
compared with most of the other groups.
The change of GluA1 expression in our TBI model is in agreement with previous results
showing increased levels of GluA1 in patients with TBI (Atkins, 2006). The increased
expression of GluA1indicates an elevated level of homomeric GluA1 receptor. GluA1 receptors
are permeable to calcium, and their dysregulation could allow for an unchecked influx of Ca2+.
Allowing an unrestrained influx of Ca2+ produces the activation of the calcium/calmodulindependent protein kinases (CaMKs). CaMKs regulates vital functions in the brain, including
neurotransmitter synthesis and release, modulation of ion channel activity, cellular transport, cell
morphology and neurite extension, synaptic plasticity during learning and memory, and
immediate early gene expression (Yamauchi, 2005). The consequence of the increased
expression of GluA1 could signal the unbound influx of Ca2+ that might reach toxic levels
contributing to cell death.
The finding that the increase of protein expression in the non-injured side was
significantly different from the injured side, with the injured side showing lower levels of
GluA1, suggests that GluA1 may be activated as a compensatory mechanism to preserve the
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AMPAR subunit's functions in the hippocampus. Previous studies have shown that TBI produces
compensatory connectivity mechanisms between affected cortical and subcortical brain regions
in humans (Iraji et al., 2016). It has been shown, in animal studies, that mice lacking the Gria1,
the gene that encodes GluA1, engage the trafficking and insertion of GluA2 and GluA3 subunits
during LTP. These results suggest that in the absence of GluA1, there is a compensatory
mechanism employed by AMPAR (Romberg et al., 2009). A similar compensatory mechanism
could be occurring in the injured and uninjured hippocampus that only involves the regulation of
GluA1. Further studies looking at the compensatory mechanism of AMPAR after TBI are
needed.
Furthermore, since the effects on the hippocampus were delayed (i.e., three weeks after
CCI), the elevated level of GluA1 could represent a shift in the basal receptor expression as it has
been demonstrated that tonic glutamate increases more than 200% in the hippocampus after TBI
(Hinzman et al., 2010). The levels of GluA1 in the CCI injured side did not reach statistically
significant; however, a tendency of increased level can be observed. The remaining groups did
not alter their levels of GluA1, which is critical when comparing the LEV and BREV groups
with the Sham group. That these groups have levels of GluA1 that are not drastically dissimilar
suggests that the AEDs could be modulating the activation of this AMPA subunit.
The GluA2 subunit is also modulated in our experimental paradigm. In the CCI group, a
drastic difference between the non-injured and injured sides can be observed. This was seen as
an increase in GluA2 in the non-injured hemisphere and a decrease in the injured hemisphere in
the CCI condition. This pattern is in agreement with previous findings showing a decrease of
GluA2 in injured rats' hippocampus (Bell et al., 2007; Bell et al., 2009). The mechanism of
action for this decrement could be attributed to the excessive neuronal cell loss after TBI (Sato,
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Chang, Igarashi, & Noble, 2001) and, therefore, the downregulation of synaptic receptors.
Furthermore, the increment of GluA2 in the non-injured side suggests that a compensatory
mechanism is being engaged after the delayed effects of TBI. Since GluA2 is the AMPA subunit
that regulates excessive calcium influx into the cell and thus, protects against the excitotoxic
effects of increased calcium, the non-injured side can be counteracting the adverse effects of CCI
as a result of the low levels of GluA2 in the injured side. In contrast to the CCI group results, the
LEV group shows an increase of GluA2 in the injured side. This result suggests that the AED
LEV reduces the delayed and harmful effects caused by TBI in the injured side; thus, the
compensatory mechanism that appears to be engaged in the CCI non-injured group does not
become active in the presence of LEV. While the effects of AEDs described in this study have
not been reported elsewhere, an investigation has shown increase levels of glutamate transporter1 (GLT-1) in the hippocampus of LEV treated rodents. The increased levels of GLT-1 indicate
the fast clearing of glutamate neurotransmitter from the synaptic space (Ueda et al., 2007),
preventing the buildup of lethal levels of glutamate.
Protein expression ratio between GluA1 and GluA2 was quantified to compare the levels
of AMPAR between conditions and reveal the extent to which each subunit was being trafficked.
Analysis of the subunit ratios showed an elevated level of the GluA1 subunit in the CCI injured
side group compared with all other groups. The rise in the number of GluA1 receptors suggests
that after CCI, the injured hippocampus upregulates more GluA1 than GluA2, consistent with a
previous investigation showing an increase of the GluA1 subunit after TBI (REF). As described
above, the homomeric GluA1 is calcium-permeable, allowing Ca2+ to flow unimpeded into the
cell and could lead to dysregulation in downstream signaling pathways (Atkins et al., 2006;
Weber, 2012).
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The protein ratio in the BREV and LEV shows a decrease in the level of GluA1 in the
injured side group compared with their non-injured counterparts and with the CCI group. The
downregulation of GluA1 indicated an increased presence of the GluA2 subunit at the synapse.
Given these results, it appears the AEDs may be modulating the AMPARs by two distinct
mechanisms; [1] AEDs could downregulate GluA1 by preventing the formation of homomeric
receptors permeable to calcium, and [2] they could increase the cycling and insertion of the
GluA2 subunit into the synapse and prevent extreme inflow of Ca2+. Although these
mechanisms are speculative, at best, they fit with what we know about AMPAR cycling and
trafficking (Bredt & Nicoll, 2003; Shi et al., 2001).
The modulation of AMPAR by these AEDs could play a role in the observed increase in
cognitive functions shown by patients taking LEV. Magalhaes et al. (2015) found that LEV
improves working memory, inhibitory control of attention, and decision making (Magalhaes et
al., 2015). Another study compared the effects of LEV and valproate (VPA, another AED) on
cognitive functions. The researchers found increases in cognitive abilities, including visual
search, scanning, processing speed, and executive functioning (El Sabaa, Hamdi, Hamdy, &
Sarhan, 2020). Either investigation did not assess the molecular mechanisms of cognitive
improvements produced by LEV. Recently, an animal study looked at the effects of LEV and
VPA on LTP and cognitive function in the hippocampus of epileptic rodents. Lamberty et al.
(2020) showed that animals treated with VPA have lower excitatory postsynaptic potentials
(EPSP) than animals treated with LEV; furthermore, LEV treated rodents showed cognitive
abilities comparable to control animals. These findings suggest that LEV affects cognitive
function by modulating LTP (Lamberty, Margineanu, & Klitgaard, 2000). Because AMPARs
play an essential role in LTP and memory [for review, see; (Diering & Huganir, 2018; Malinow
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& Malenka, 2002)], it is tempting to suggest that AMPAR modulation by LEV might
significantly enhance cognitive functions. Further research is needed to investigate these
molecular mechanisms of increase cognitive function after LEV treatment.
10. Limitations
As with any studies, this investigation has some limitations. For instance, the only region
examined in this report was the hippocampus, as it is relevant to epilepsy. However, the cortex is
the brain area that receives the full force of the impact after CCI, and, therefore, its examination
is warranted in future studies. Additionally, although the mechanisms of how BREV and LEV
are modulating AMPAR have been describe in the literature, they are not they are not fully
elucidated. The AEDs can be acting on another molecular mechanism such as glutamate
transporters or scaffolding proteins that support the insertion of AMPAR into the synapse.
Further investigation is needed to reveal the mechanisms involved fully.
11. Conclusion

During the last decades, extensive research has provided us with great insight into the
pathophysiology of TBI. For instance, TBI primary brain injury is immediate and
irreversible. TBI secondary brain injury produces a cascade of molecular disruptions at the
functional and structural level, and it can be treated due to its delayed nature. Secondary
injury can lead to the abnormal function of glutamate receptors caused by the unrestrained
release of glutamate, leading to excitotoxicity and the development of PTE. Up to date, many
pharmacological strategies have been used to ameliorate the effects of TBI secondary injury,
including PTE. However, many of the drugs aimed at reducing these symptoms have failed.
In search of better pharmacological agents, the anti-epileptic drugs BREV and LEV have
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been used effectively to treat PTE; however, knowledge about the mechanism of actions of
these drugs is still being compiled. Although much is known about glutamate AMPA
receptor's role in memory and learning, one of their primary functions is controlling calcium
influx into the cell. BREV and LEV appear to be modulating this AMPA receptor function to
exert their effects after secondary injury.
The complete mechanism of actions of many of these drugs aimed at treating
symptoms of secondary injury is still incomplete. A better understanding of the molecular
mechanism engaged by these drugs is needed to develop improved treatment strategies. One
possibility for the lack of positive results after using these drugs could be that one specific
drug can only treat one specific symptom produced by one specific molecular disruption. In
this investigation, we see that the AEDs BREV and LEV modulate AMPA receptor's
function. Because secondary injury produces a whole cascade of disruptions, co-treatment
with other drugs could benefit TBI patients. Additional research is needed to develop better
therapeutics that could ameliorate the symptoms of all those suffering from TBI.
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12. Tables and Figures
Figure 1.
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Note. Figure 1 shows the GluA1 hippocampal expression for all the groups showing an overall
effect of condition and an overall effect of site of injury. **p < 0.01; *p < 0.05.
Figure 2.
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Note. Figure 1 shows the GluA2 hippocampal expression for all the groups showing an overall
effect of condition and an interaction. **p < 0.01; *p < 0.05.

34

Figure 3.
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Note. Figure 1 shows the GluA1/GluA2 ratio for all the groups showing an overall effect of
condition and a significant interaction. **p < 0.01; *p < 0.05.
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Table 1.
GluA1 and GluA2 Significant Pairwise Comparisons
GluA1

GluA2

Mean Diff

p

t

Mean Diff

p

t

SHAM: non-injured vs. CCI: non-injured

-21186

<.001

4.46

-15354

.002

4.256

SHAM: injured vs. CCI: non-injured

-26018

<.001

4.63

-23414

<.001

5.346

SHAM: injured vs. LEV: injured

-----

----

-----

-20372

.004

4.102

CCI: non-injured vs. CCI: injured

-----

----

-----

26925

<.001

7.057

CCI: non-injured vs. BREV: non-injured

26583

<.001

5.742

24121

<.001

6.686

CCI: non-injured vs. BREV: injured

28022

<.001

6.053

15139

.003

4.196

CCI: non-injured vs. LEV: non-injured

19089

.036

3.397

20118

<.001

4.593

CCI: injured vs. LEV: injured

23573

.003

4.195

-----

----

-----

CCI: injured vs. LEV: injured

-----

----

-----

-23883

<.001

5.335

BREV: non-injured vs. LEV: injured

-----

----

-----

-21079

<.001

4.901

LEV: non-injured vs. LEV: injured

-----

----

-----

-17076

.032

3.438

Table 2.
GluA1/GluA2 Ratio Significant Pairwise Comparisons
GluA2/GluA1
Mean Diff

p

t

SHAM: non-injured vs. CCI: injured

-1.124

<.001

7.91

SHAM: non-injured vs. BREV: injured

0.458

.047

3.31

SHAM: injured vs. CCI: Ipsilateral

-1.093

<.001

6.50

CCI: non-injured vs. CCI: injured

-1.063

<.001

7.48

CCI: non-injured vs. BREV: injured

0.519

.012

3.75

CCI: non-injured vs. LEV: injured

0.571

.036

3.39

CC: injured vs. BREV: non-injured

1.128

<.001

8.17

CCI: injured vs. BREV: injured

1.582

<.001

11.42

CCI: injured vs. LEV: non-injured

0.889

<.001

5.29
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CCI: injured vs. LEV: injured

1.634

<.001

9.72

BREV: non-injured vs. BREV: injured

0.453

.039

3.37

BREV: injured vs. LEV: non-injured

-0.692

.003

4.19

LEV: non-injured vs. LEV: injured

0.745

.007

3.91
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